Yujing Xin

机构：Shandong Provincial Hospital, Shandong First Medical University

发表论文 32 篇 · 总被引 663 次 · h-index 15

代表论文

• Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study (2024 · EClinicalMedicine · 被引 154)
• Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma (2023 · Hepatology International · 被引 60)
• Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma (2022 · Frontiers in Immunology · 被引 51)
• Prognostic effect of albumin-to-alkaline phosphatase ratio on patients with hepatocellular carcinoma: a systematic review and meta-analysis (2023 · Scientific Reports · 被引 30)
• A Systemic Inflammation Response Index (SIRI)-Based Nomogram for Predicting the Recurrence of Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation (2021 · CardioVascular and Interventional Radiology · 被引 28)
• Predictors and patterns of recurrence after radiofrequency ablation for hepatocellular carcinoma within up-to-seven criteria: A multicenter retrospective study (2021 · European Journal of Radiology · 被引 24)